Retrospective Multicenter Outcomes Study of Oligo-Metastatic and Oligo-Recurrent Cervical Cancer

What this Trial Is About

Researchers are investigating outcomes in patients with oligo-metastatic and oligo-recurrent cervical cancer, focusing on how local treatments like radiation therapy combined with systemic chemotherapy affect survival and disease progression. This multicenter, retrospective registry study aims to fill gaps in knowledge about which patients benefit most from radiation at primary and metastatic sites, how re-irradiation impacts outcomes, and the toxicity associated with these treatments. The study will also develop risk groups and a nomogram to predict patient outcomes, supporting future research. The study collects anonymized data from multiple centers on patients with oligo-metastatic or oligo-recurrent cervical cancer, some treated with radiation, chemotherapy, immunotherapy, or targeted agents, and others with local therapies such as surgery or ablation. Treatments analyzed include high-dose radiation, stereotactic ablative radiation, and re-irradiation. The registry uses standardized electronic forms to gather detailed clinical information, including treatment doses and responses, while ensuring data quality through validation and oversight. Participants' medical records from about 350-400 patients treated between 2007 and 2021 will be reviewed without direct patient contact. The study measures overall survival over four years as the primary outcome, with secondary outcomes including progression-free survival, dose-response relationships, and severe adverse events. Data will be analyzed statistically to identify risk factors and treatment effects, with all procedures performed under strict data protection and ethical approvals.

Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.